IP Ownership · Gene Editing
Who owns the CRISPR patents?
CRISPR-Cas9, base editing, prime editing, and precision genome engineering technologies.
Patents indexed
21
Total citations
19,867
Top-3 hold
97% of citations
Assignees ranked
10
Ranked by total forward citations — 10 companies
How to Make Many Copies of a Specific DNA Segment
US 4683202 · 7,558 citations
49%
of citations
Making Hybrid Antibodies from Different Animals
US 4816567 · 8,214 citations
41%
of citations
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 8697359 · 1,268 citations
6%
of citations
How to Make Human Erythropoietin (EPO) Using Engineered DNA
US 4703008 · 346 citations
2%
of citations
How an mRNA Vaccine Targets Prostate Cancer with Six Antigens
US 20160166668 · 84 citations
1%
of citations
How Genetically Modified T-Cells Attack Cancer
US 9328156 · 65 citations
1%
of citations
How CRISPR-Cas9 Uses RNA to Edit DNA
US 10113167 · 49 citations
0%
of citations
Using Synthetic DNA Fragments to Block HIV Replication
US 5110802 · 26 citations
0%
of citations
How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer
US 10314897 · 4 citations
0%
of citations
Boosting Plant Gene Editing and Regeneration with Special Genes
US 12416013 · 1 citations
0%
of citations
Rankings by total forward citations within PatentBrief's enriched patent corpus for the Gene Editing technology domain. Forward citations are the industry standard proxy for patent influence and commercial importance. Coverage reflects patents currently indexed; the full USPTO corpus is larger.